HomeAI · summaries
Storia in 20 fonti
Eli Lilly: Next-gen weight loss drug may be more effective than others - UPI.com
Eli Lilly's weight loss drug retatrutide helped nearly half of participants in a phase 3 trial to lose more than 30% of their weight after two years.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
Retatrutide induces ‘impressive’ weight loss of up to 28.3% for adults with obesity
A once-weekly triple receptor agonist conferred up to 28.3% weight loss at 80 weeks for adults with overweight or obesity, according to topline results from a phase 3 trial. As…
- ·
nbcnews.com
People lost up to 85 pounds on Lilly’s experimental weight loss drug, company says
The results — the most weight loss ever seen in a medication trial — put the drug’s effectiveness on par with bariatric surgery.
- ·
statnews.com
Lilly’s ‘triple-G’ drug leads to bariatric-surgery levels of weight loss in trial
A next-gen Eli Lilly obesity drug led to bariatric-surgery levels of weight loss in a study, but also saw patients dropping out because of side effects.
- ·
cnbc.com
Eli Lilly says next-generation weight loss drug clears crucial obesity trial
The results bring Lilly one step closer to filing for approval of the injection, retatrutide, which works differently from existing injections and pills.
- ·
endpoints.news
Lilly’s triple agonist still leads among late-stage obesity assets
Eli Lilly said Thursday that its triple agonist retatrutide allowed obesity patients to lose about a quarter of their weight after taking the shot for 80 weeks. This is the…
- ·
milanofinanza.it
Eli Lilly, il farmaco anti-obesità che sfida la chirurgia bariatrica: fino al 28% di peso in meno e debutto nel 2027 | MilanoFinanza News
I pazienti che sono riusciti a tollerare per un anno e mezzo la dose più alta del farmaco Retatrutide hanno perso in media il 28,3% del loro peso corporeo. Batte il Wegovy di Novo…
- ·
qz.com
Eli Lilly retatrutide Phase 3 obesity trial results 2026
The triple-hormone injection outpaced existing weight loss drugs and approached bariatric surgery outcomes in an 80-week study
- ·
thehindubusinessline.com
Eli Lilly says next-gen obesity drug helps patients lose 28% of body weight
Eli Lilly's retatrutide shows promise, helping obesity patients lose over 28% of their weight in a key trial.
- ·
eu.usatoday.com
New weight-loss shot more powerful than old GLP-1s, Eli Lilly says
Lilly said people on the next-generation weight loss medication across three different dosages achieved weight loss of 19% to 28%.
- ·
zerohedge.com
Lilly's Next-Gen Weight-Loss Drug Clears Trial With Near-Bariatric Surgery Results
"We're in a zone that's historically been associated with bariatric surgery, and you're getting it with a medicine."
- ·
valor.globo.com
Eli Lilly diz que novo medicamento ajuda pacientes com obesidade a perder 28% do peso corporal
Resultados do Retatrutida ao longo de um ano e meio, em um estudo, abrem caminho para que a empresa busque aprovação regulatória e lance o medicamento no próximo ano
- ·
independent.co.uk
Super Ozempic? New weight-loss drug sees even better results in recent study
Many of the patients who tested the drug lost about 30 percent of their body weight — a loss comparable to the result of bariatric surgery
- ·
scientificamerican.com
Trial of next-gen weight-loss drug retatrutide shows users lose almost a third of their body weight
While drugs such as Wegovy target a single gut hormone, retatrutide is among a new class of GLP-1 drugs that aims at three hormone receptors
- ·
washingtonexaminer.com
New Eli Lilly weight loss drug has dramatic effects in clinical trial
A new weight loss drug from Eli Lilly made patients lose 28% of their body weight on average, levels achieved only by surgery before.
- ·
time.com
A Next-Generation Drug Causes Dramatic Weight Loss, Eli Lilly Says
Retatrutide, an experimental injectable drug, targets three hormones related to weight loss.
- ·
economictimes.indiatimes.com
Eli Lilly’s obesity drug shows up to 30% weight loss in trial
Eli Lilly's new obesity drug retatrutide shows remarkable results. In a major trial, patients lost up to 30% of their body weight. This once-weekly injection targets multiple…
- ·
benzinga.com
Eli Lilly's Triple Hormone Obesity Drug Shows Significant Weight Loss - Eli Lilly (NYSE:LLY)
Eli Lilly says retatrutide helped obesity trial participants lose up to 28.3% body weight in the Phase 3 TRIUMPH-1 study.
- ·
upi.com
Eli Lilly: Next-gen weight loss drug may be more effective than others - UPI.com
Eli Lilly's weight loss drug retatrutide helped nearly half of participants in a phase 3 trial to lose more than 30% of their weight after two years.
- ·
expansion.com
La retatrutida de Eli Lilly reduce la obesidad en un 30% a los dos a�os de tratamiento
Los resultados preliminares del estudio TRIUMPH-1 confirman resultados anteriores en fase II de la retatrutida (LY3437943), f�rmaco en fase experimental de la familia de los…
- ·
g1.globo.com
Nova caneta contra obesidade leva pacientes a perder até 32 kg em estudo de fase 3 | G1
Retatrutida, molécula da Eli Lilly ainda em investigação, mostrou perda média de 28,3% do peso corporal em 80 semanas; resultado se aproxima de índices observados em cirurgias…